Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease

Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease

US Patent 10155027 · Granted Dec 18, 2018

Estimated economic value: $20,780,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

High concentration alpha-glucosidase compositions for the treatment of Pompe dis2025
High concentration alpha-glucosidase compositions for the treatment of Pompe dis2025
Augmented acid alpha-glucosidase for the treatment of Pompe disease2025
Recombinant human acid alpha-glucosidase2025
High concentration alpha-glucosidase compositions for the treatment of Pompe dis2022
High concentration alpha-glucosidase compositions for the treatment of Pompe dis2022
Augmented acid alpha-glucosidase for the treatment of Pompe disease2022
Augmented acid alpha-glucosidase for the treatment of Pompe disease2020
High concentration alpha-glucosidase compositions for the treatment of pompe dis2019
High concentration alpha-glucosidase compositions for the treatment of pompe dis2019
α-galactosidase A and 1-deoxygalactonojirimycin co-formulation2019
α-galactosidase A and 1-deoxygalactonojirimycin co-formulation2019